Radiotherapy for patients with locoregional and oligometastatic relapses of prostate cancer after radical prostatectomy

Materials and methods. In our study, 21 patients with recurrent prostate cancer after radical prostatectomy and oligometastases were treated by salvage radiation therapy, which included radiotherapy treatment of recurrent tumors, regional pelvic lymph nodes, the prostate bed and stereotactic body radiation therapy to detected solitary metastases.Results. The average follow-up period was 19 ± 3.5 months. At the same time, 12 (57 %) of 21 patients are currently under observation for more than 1 year, and 1 patient for more than 5 years without signs of a biochemical recurrence. The indicator of biochemical control of the disease was 86 % (18 / 21 patients) with an average follow-up period of 19 months.Conclusion. It seems to us that further study of this problem can replace today's palliative standard of treatment for this special category of patients — hormonal and chemotherapy treatment, which has low effectiveness at a high incidence of toxicity.

[1]  V. Matveev,et al.  Prostate-specific antigen is a predictor of the efficacy of salvage radiation therapy in patients with recurrent prostate cancer after radical prostatectomy , 2019, Cancer Urology.

[2]  V. Matveev,et al.  Простатспецифический антиген – предиктор эффективности спасительной лучевой терапии больных с рецидивами рака предстательной железы после радикальной простатэктомии , 2019 .

[3]  Ситдиков Айрат Габитович,et al.  Об основных итогах научной деятельности института археологии им. А. Х. Халикова Академии наук Татарстана в 2017 году , 2018 .

[4]  Суконко Олег Григорьевич,et al.  Рак предстательной железы у пациентов с метаболическими нарушениями , 2020 .

[5]  Владимир Борисович Матвеев,et al.  «Спасительная» лучевая терапия после радикальной простатэктомии с использованием последних достижений в радиационной онкологии , 2018 .

[6]  Henry Knipe,et al.  Oligometastases , 2016, Radiopaedia.org.

[7]  S. Fanti,et al.  Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy , 2015, The Journal of Nuclear Medicine.

[8]  M. Schwaiger,et al.  Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy , 2015, The Journal of Nuclear Medicine.

[9]  F. Montorsi,et al.  Natural history of surgically treated high-risk prostate cancer. , 2015, Urologic oncology.

[10]  N. Corcoran,et al.  Advances in local and ablative treatment of oligometastasis in prostate cancer , 2014, Asia-Pacific journal of clinical oncology.

[11]  A. Kawashima,et al.  Early localization of recurrent prostate cancer after prostatectomy by endorectal coil magnetic resonance imaging. , 2014, The Canadian journal of urology.

[12]  Артемов Артем Викторович,et al.  Применение митомицина в лечении рубцовых осложнений после радикальной простатэктомии , 2014 .

[13]  C. Pelizzari,et al.  Evaluation of the prostate bed for local recurrence after radical prostatectomy using endorectal magnetic resonance imaging. , 2013, International journal of radiation oncology, biology, physics.

[14]  P. Gabriele,et al.  Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging , 2009, European Radiology.

[15]  Roberto Passariello,et al.  Role of dynamic contrast-enhanced magnetic resonance (MR) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer. , 2008, European urology.

[16]  M. Kattan Re: Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy gleason score (Partin Tables) based on cases from 2000 to 2005. , 2007, European urology.

[17]  Alan W Partin,et al.  Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. , 2007, Urology.

[18]  Matthias D Hofer,et al.  Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. , 2007, Human pathology.

[19]  K. Haustermans,et al.  A pretreatment table for the prediction of final histopathology after radical prostatectomy in clinical unilateral T3a prostate cancer. , 2007, European urology.

[20]  Anthony V D'Amico,et al.  Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. , 2007, The Journal of urology.

[21]  M. Kattan,et al.  Management of prostate‐specific antigen relapse in prostate cancer: A European consensus , 2004, International journal of clinical practice.